ASTRAZENECA PLC DL-,25
[WKN: 886455 | ISIN: GB0009895292]
Aktienkurse
141,600€ -0,18%
Echtzeit-Aktienkurs ASTRAZENECA PLC DL-,25
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

Director/PDMR Shareholding

15 May 2024 15:00 BST Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that on 13 May 2024, Pascal…

AstraZeneca: Vor großem Kaufsignal - Aktienanalyse

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

AstraZeneca completes Cellectis equity investment

7 May 2024 AstraZeneca completes equity investment agreement with Cellectis AstraZeneca today announced the successful completion of an equity investment with Cellectis,…

Calquence combination improved PFS in 1L MCL

02 May 2024 Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO…

Total Voting Rights

1 May 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

Truqap recommended for EU breast cancer approval

29 April 2024 Truqap plusFaslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer Recommendation based on CAPItello-291 results…

Enhertu improved PFS in HER2-low and ultralow

29 April 2024 Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one…

JEFFERIES stuft ASTRAZENECA auf Hold

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Astrazeneca nach Quartalszahlen auf "Hold" mit einem Kursziel von 11000 Pence…

AstraZeneca schneidet besser ab als erwartet

(Reuters) - Der Pharmakonzern AstraZeneca hat von der steigenden Nachfrage nach seinen Blockbuster-Medikamenten profitiert und zum Jahresauftakt einen unerwartet starken…